BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
Rhea-AI Summary
BioHarvest Sciences (NASDAQ: BHST) will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The company will host a conference call and live webcast at 4:30 PM Eastern Time to discuss results and business updates.
Investors can register for the live webcast and replay will be posted in the Investor Relations/Events & Presentations section of the company's website.
Positive
- None.
Negative
- None.
News Market Reaction – BHST
On the day this news was published, BHST declined 4.60%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BHST is up 10.12% with elevated volume while sector peers show mixed moves: some down (e.g., ATPC -8.59%, BYND -5.00%) and others up (e.g., HAIN +3.38%, BRCC +6.43%). Momentum data flags 2 peers moving up and 2 down, suggesting broader sector dynamics alongside stock-specific trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Board transition | Neutral | -3.7% | Long-serving director resigned; Prof. Hezi Levy appointed to the board. |
| Mar 03 | Conference participation | Positive | -2.4% | Participation in Roth Conference and update on funding and growth focus. |
| Jan 07 | Year-end update | Positive | +3.7% | Reported strong revenue run rate, margins, and financing for expansion. |
| Dec 18 | Government grant | Positive | +1.1% | $1.6M Israeli Innovation Authority grant for second-generation platform. |
| Dec 03 | Product launch | Positive | +3.0% | Launch of VINIA Blood Flow Hydration into U.S. electrolyte drink market. |
Recent company news (product launches, grants, and operational updates) often saw modest positive price reactions, while conference participation and board changes were followed by small declines.
Over the last few months, BioHarvest reported several operational milestones. A year-end update highlighted an annualized revenue run rate above US$36 million with gross margins over 60%, and a new VINIA product launch targeted the $13 billion U.S. electrolyte drink market. The company also secured a $1.6 million Israeli Innovation Authority grant and raised about $30.8 million in 2025. Against this backdrop, today’s announcement simply sets the timing for releasing Q4 and full-year 2025 financials.
Market Pulse Summary
This announcement sets the timing for BioHarvest’s fourth quarter and full-year 2025 results, with a release and earnings call scheduled for March 31, 2026 at 4:30 p.m. Eastern Time. In recent updates, the company highlighted revenue growth, strong margins, and product and CDMO expansion. Investors may focus on how the upcoming report tracks against the previously stated US$36 million run rate, margin profile, and financing-supported growth plans.
AI-generated analysis. Not financial advice.
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on business operations.
Fourth Quarter and Full Year 2025 Earnings Call
Date: Tuesday, March 31, 2026
Time: 4:30 PM Eastern Time
Webcast link: https://events.q4inc.com/attendee/512060117
The Earnings call webcast will be broadcast live, and attendees are encouraged to register via the webcast link at least 10 minutes prior to the call to ensure timely participation.
The webcast recording will be available for replay on the Company's website within the Investor Relations/Events & Presentations section.
About BioHarvest Sciences
BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. Forward-looking statements include those set forth in the Risk Factors section of the Company's Securities and Exchange Commission (SEC)'s filings which can be found within the Investor Relations section on the Company's website, or on the SEC's website at http://www.sec.gov.
BioHarvest Corporate Contact:
Dave Ryan
(604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288805
FAQ
When will BioHarvest (BHST) release fourth quarter and full year 2025 results?
What time is the BioHarvest (BHST) earnings call on March 31, 2026?
How can investors access the BioHarvest (BHST) March 31, 2026 webcast?
Will BioHarvest (BHST) provide a replay of the March 31, 2026 earnings webcast?
What topics will BioHarvest (BHST) cover during the March 31, 2026 earnings call?
